Critical Contrast: Surrozen (SRZN) and Its Rivals

Surrozen (NASDAQ:SRZN) is one of 844 public companies in the “Biotechnology” industry, but how does it weigh in compared to its peers? We will compare Surrozen to similar companies based on the strength of its dividends, earnings, analyst recommendations, risk, profitability, institutional ownership and valuation.

Profitability

This table compares Surrozen and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Surrozen	-2,885.33%	N/A	-93.62%
Surrozen Competitors	-9,051.23%	-201.20%	-30.64%

Analyst Ratings

This is a summary of current recommendations for Surrozen and its peers, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Surrozen	1	1	4	1	2.71
Surrozen Competitors	9793	15073	45360	1575	2.54

Surrozen currently has a consensus target price of $48.33, suggesting a potential upside of 61.00%. As a group, “Biotechnology” companies have a potential upside of 99.38%. Given Surrozen’s peers higher possible upside, analysts plainly believe Surrozen has less favorable growth aspects than its peers.

Earnings & Valuation

This table compares Surrozen and its peers top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Surrozen	$3.48 million	-$242.03 million	-0.74
Surrozen Competitors	$727.61 million	$12.25 million	-9.95

Surrozen’s peers have higher revenue and earnings than Surrozen. Surrozen is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Insider & Institutional Ownership

66.6% of Surrozen shares are owned by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are owned by institutional investors. 31.7% of Surrozen shares are owned by insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Risk & Volatility

Surrozen has a beta of 0.51, suggesting that its stock price is 49% less volatile than the S&P 500. Comparatively, Surrozen’s peers have a beta of 1.15, suggesting that their average stock price is 15% more volatile than the S&P 500.

Summary

Surrozen beats its peers on 7 of the 13 factors compared.

Surrozen Company Profile

Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.